Honorary Professor Garry Graham.
Allopurinol
Enantiomers
Gold
Ibuprofen
Nonsteroidal anti-inflammatory drugs
Paracetamol
Pharmacokinetics
Salicylates
Journal
Inflammopharmacology
ISSN: 1568-5608
Titre abrégé: Inflammopharmacology
Pays: Switzerland
ID NLM: 9112626
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
received:
19
08
2021
accepted:
25
08
2021
pubmed:
18
9
2021
medline:
3
2
2022
entrez:
17
9
2021
Statut:
ppublish
Résumé
An appreciation of the contribution of Professor Gary Graham to anti-inflammatory and antirheumatic pharmacology and clinical pharmacology.
Identifiants
pubmed: 34533655
doi: 10.1007/s10787-021-00872-1
pii: 10.1007/s10787-021-00872-1
doi:
Substances chimiques
Anti-Inflammatory Agents
0
Antirheumatic Agents
0
Types de publication
Biography
Historical Article
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1255-1259Sujets (noms de personnes)
{'last_name': 'Graham', 'fore_name': 'Garry', 'initials': 'G'}
Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Bochner F, Graham GG, Cham BE, Imhoff DM, Haavisto TM (1981) Salicylate metabolite kinetics after several salicylates. Clin Pharmacol Ther 30:266–275. https://doi.org/10.1038/clpt.1981.158
doi: 10.1038/clpt.1981.158
pubmed: 7249509
Champion GD, Graham GG (1978) Pharmacokinetics of non-steroidal anti-inflammatory agents. Aust N Z J Med 8:94–100. https://doi.org/10.1111/j.1445-5994.1978.tb04794.x
doi: 10.1111/j.1445-5994.1978.tb04794.x
pubmed: 365162
Champion GD, Day RO, Graham GG, Paull PD (1975) Salicylates in rheumatoid arthritis. Clin Rheum Dis 1:245–265. https://doi.org/10.1016/S0307-742X(21)00120-X
doi: 10.1016/S0307-742X(21)00120-X
Champion GD, Cairns DR, Bieri D, Adena MA, Browne CD, Cohen ML, Day RO, Edmonds JP, Graham GG, de Jager J et al (1988) Dose response studies and longterm evaluation of auranofin in rheumatoid arthritis. J Rheumatol 15:28–34
pubmed: 3280795
Day RO, Graham GG, Champion GD, Lee E (1984) Anti-rheumatic drug interactions. Clin Rheum Dis 10:251–275. https://doi.org/10.1016/S0307-742X(21)00501-4
doi: 10.1016/S0307-742X(21)00501-4
pubmed: 6150784
Day RO, Furst DE, Dromgoole SH, Paulus HE (1988a) Changes in salicylate serum concentration and metabolism during chronic dosing in normal volunteers. Biopharm Drug Dispos 9:273–283. https://doi.org/10.1002/bod.2510090306
doi: 10.1002/bod.2510090306
pubmed: 3395669
Day RO, Graham GG, Williams KM, Brooks PM (1988b) Variability in response to NSAIDs. Fact or fiction? Drugs 36:643–651. https://doi.org/10.2165/00003495-198836060-00001
doi: 10.2165/00003495-198836060-00001
pubmed: 3065056
Day RO, Harris G, Brown M, Graham GG, Champion GD (1988c) Interaction of salicylate and corticosteroids in man. Br J Clin Pharmacol 26:334–337. https://doi.org/10.1111/j.1365-2125.1988.tb05286.x
doi: 10.1111/j.1365-2125.1988.tb05286.x
pubmed: 3179172
pmcid: 1386548
Day RO, Miners J, Birkett DJ, Graham GG, Whitehead A (1988d) Relationship between plasma oxipurinol concentrations and xanthine oxidase activity in volunteers dosed with allopurinol. Br J Clin Pharmacol 26:429–434. https://doi.org/10.1111/j.1365-2125.1988.tb03402.x
doi: 10.1111/j.1365-2125.1988.tb03402.x
pubmed: 3190993
pmcid: 1386565
Day RO, Miners JO, Birkett DJ, Whitehead A, Naidoo D, Hayes J, Savdie E (1988e) Allopurinol dosage selection: relationships between dose and plasma oxipurinol and urate concentrations and urinary urate excretion. Br J Clin Pharmacol 26:423–428. https://doi.org/10.1111/j.1365-2125.1988.tb03401.x
doi: 10.1111/j.1365-2125.1988.tb03401.x
pubmed: 3190992
pmcid: 1386564
Day RO, Graham GG, Bieri D, Brown M, Cairns D, Harris G, Hounsell J, Platt-Hepworth S, Reeve R, Sambrook PN, &, et al (1989) Concentration-response relationships for salicylate-induced ototoxicity in normal volunteers. Br J Clin Pharmacol 28:695–702. https://doi.org/10.1111/j.1365-2125.1989.tb03562.x
doi: 10.1111/j.1365-2125.1989.tb03562.x
pubmed: 2611090
pmcid: 1380040
Day RO, Williams KM, Graham S, Handel M (1991) The pharmacokinetics of total and unbound concentrations of tenoxicam in synovial fluid and plasma. Arthritis Rheum 34:751–760. https://doi.org/10.1002/art.1780340617
doi: 10.1002/art.1780340617
pubmed: 2053921
Day RO, Francis H, Vial J, Geisslinger G, Williams KM (1995) Naproxen concentrations in plasma and synovial fluid and effects on prostanoid concentrations. J Rheumatol 22:2295–2303
pubmed: 8835565
Day RO, McLachlan AJ, Graham GG, Williams KM (1999) Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet 36:191–210. https://doi.org/10.2165/00003088-199936030-00002
doi: 10.2165/00003088-199936030-00002
pubmed: 10223168
Emori HW, Champion GD, Bluestone R, Paulus HE (1973) Simultaneous pharmacokinetics of indomethacin in serum and synovial fluid. Ann Rheum Dis 32:433–435. https://doi.org/10.1136/ard.32.5.433
doi: 10.1136/ard.32.5.433
pubmed: 4751781
pmcid: 1006141
Graham G, Rowland M (1972) Application of salivary salicylate data to biopharmaceutical studies of salicylates. J Pharm Sci 61:1219–1222. https://doi.org/10.1002/jps.2600610810
doi: 10.1002/jps.2600610810
pubmed: 5050370
Graham G, Scott K (2003) Mechanisms of action of paracetamol and related analgesics. Inflammopharmacology 11:401–413. https://doi.org/10.1163/156856003322699573
doi: 10.1163/156856003322699573
pubmed: 15035793
Graham GG, Scott KF (2005) Mechanism of action of paracetamol. Am J Ther 12:46–55. https://doi.org/10.1097/00045391-200501000-00008
doi: 10.1097/00045391-200501000-00008
pubmed: 15662292
Graham GG, Champion GD, Day RO, Paull PD (1977) Patterns of plasma concentrations and urinary excretion of salicylate in rheumatoid arthritis. Clin Pharmacol Ther 22:410–420. https://doi.org/10.1002/cpt1977224410
doi: 10.1002/cpt1977224410
pubmed: 902454
Graham GG, Champion GD, Haavisto TM, McNaught PJ (1981) Gold binding to red blood cells. Ann Rheum Dis 40:210. https://doi.org/10.1136/ard.40.2.210-a
doi: 10.1136/ard.40.2.210-a
pubmed: 7224692
pmcid: 1000706
Graham GG, Haavisto TM, McNaught PJ, Browne CD, Champion GD (1982) The effect of smoking on the distribution of gold in blood. J Rheumatol 9:527–531
pubmed: 6813468
Graham GG, Haavisto TM, Jones HM, Champion GD (1984) The effect of cyanide on the uptake of gold by red blood cells. Biochem Pharmacol 33:1257–1262. https://doi.org/10.1016/0006-2952(84)90178-3
doi: 10.1016/0006-2952(84)90178-3
pubmed: 6424684
Graham G, Milligan M, Day R, Williams K, Ziegler J (1998) Therapeutic considerations from pharmacokinetics and metabolism Ibuprofen and paracetamol. In: Powanda M, Rainsford K (eds) Safety and efficacy of non-prescription (OTC) analgesics and NSAIDs. Springer, Dordrecht
Graham GG, Day RO, Milligan MK, Ziegler JB, Kettle AJ (1999) Current concepts of the actions of paracetamol (acetaminophen) and NSAIDs. Inflammopharmacology 7:255–263. https://doi.org/10.1007/s10787-999-0008-x
doi: 10.1007/s10787-999-0008-x
pubmed: 17638096
Graham G, Scott KF, Day R (2005) Tolerability of Paracetamol. Drug Saf 28:227–240. https://doi.org/10.2165/00002018-200528030-00004
doi: 10.2165/00002018-200528030-00004
pubmed: 15733027
Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF (2013a) The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacology 21:201–232. https://doi.org/10.1007/s10787-013-0172-x
doi: 10.1007/s10787-013-0172-x
pubmed: 23719833
Graham GG, Kannangara DRW, Stocker SL, Portek I, Pile KD, Indraratna PL, Datta I, Williams KM, Day RO (2013b) Understanding the dose-response relationship of allopurinol: predicting the optimal dosage. Brit J Clin Pharmacol 76:932–938. https://doi.org/10.1111/bcp.12126
doi: 10.1111/bcp.12126
GRAHAM GG (1988) Kinetics of non-steroidal anti-inflammatory drugs in synovial fluid. Agents Actions Suppl 24:66–75. https://doi.org/10.1007/978-3-0348-9160-8_6
doi: 10.1007/978-3-0348-9160-8_6
pubmed: 3055880
Kamel B, Graham GG, Williams KM, Pile KD, Day RO (2016) Clinical Pharmacokinetics and Pharmacodynamics of Febuxostat. Clin Pharmacokinet 56:459–475. https://doi.org/10.1007/s40262-016-0466-4
doi: 10.1007/s40262-016-0466-4
Kamel B, Graham GG, Stocker SL, Liu Z, Williams KM, Carland JE, Pile KD, Day RO (2020) A pharmacokinetic-pharmacodynamic study of a single dose of febuxostat in healthy subjects. Br J Clin Pharmacol 86:2486–2496. https://doi.org/10.1111/bcp.14357
doi: 10.1111/bcp.14357
pubmed: 32386239
Kannangara DRW, Graham GG, Wright DFB, Stocker SL, Portek I, Pile KD, Barclay ML, Williams KM, Stamp LK, Day RO (2017) Individualising the Dose of Allopurinol in Patients with Gout. Br J Clin Pharmacol 83:2015–2026. https://doi.org/10.1111/bcp.13307
doi: 10.1111/bcp.13307
pubmed: 28417592
pmcid: 5555877
Lee EJ, Williams KM, Graham GG, Day RO, Champion GD (1984) Liquid chromatographic determination and plasma concentration profile of optical isomers of ibuprofen in humans. J Pharm Sci 73:1542–1544. https://doi.org/10.1002/jps.2600731112
doi: 10.1002/jps.2600731112
pubmed: 6520754
Lee EJ, Williams K, Day R, Graham G, Champion D (1985) Stereoselective disposition of ibuprofen enantiomers in man. Br J Clin Pharmacol 19:669–674. https://doi.org/10.1111/j.1365-2125.1985.tb02694.x
doi: 10.1111/j.1365-2125.1985.tb02694.x
pubmed: 4005104
pmcid: 1463853
Lee MH, Graham GG, Williams KM, Day RO (2008) A benefit-risk assessment of benzbromarone in the treatment of gout. Was its withdrawal from the market in the best interest of patients? Drug Saf 31:643–665. https://doi.org/10.2165/00002018-200831080-00002
doi: 10.2165/00002018-200831080-00002
pubmed: 18636784
Ray JE, Wade DN, Graham GG, Day RO (1979) Pharmacokinetics of carprofen in plasma and synovial fluid. J Clin Pharmacol 19:635–643. https://doi.org/10.1002/j.1552-4604.1979.tb01626.x
doi: 10.1002/j.1552-4604.1979.tb01626.x
pubmed: 512061
Rowland M, Benet LZ, Graham GG (1973) Clearance concepts in pharmacokinetics. J Pharmacokinet Biopharm 1:123–136. https://doi.org/10.1007/BF01059626
doi: 10.1007/BF01059626
pubmed: 4764426
Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO (2008) Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 47:111–118. https://doi.org/10.2165/00003088-200847020-00004
doi: 10.2165/00003088-200847020-00004
pubmed: 18193917
Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO (2011) Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 38:904–910. https://doi.org/10.3899/jrheum.101160
doi: 10.3899/jrheum.101160
pubmed: 21285173